New Drug Combinations Improve Survival in Lung Cancer

Novartis AG (NYSE: NVS) reported data from the read more.....»»

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity.....»»

Roche's (RHHBY) late-stage lung cancer study on immuno-oncology drug, Tecentriq, meets its co-primary endpoint of progression-free survival (PFS). Roche H.....»»

read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs May 6.) read more.....»»

Shares of AstraZeneca.....»»

Merck & Co. shares slipped in the extended session Monday after the drug maker said that its lung-cancer drug Keytruda did not meet one of its endpoints in a clinical study. Merck shares declined 0......»»

The South San Francisco company's drug, currently in an early-phase clinical trial, targets types of breast and lung cancers as well as gastric cancer, which Asian drug makers are anxious to tackle......»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) 0 read more.....»»

Merck KGaA and Pfizer said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival. The cur.....»»

- To Submit New Drug Applications ("NDAs") in China for Both Non-Small Cell Lung Cancer ("NSCLC") and Chemotherapy-Induced Neutropenia ("CIN") in Q1.....»»

Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type......»»

AstraZeneca plc (NYSE: AZN) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC. read more.....»»

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Bristol-Myers Squ.....»»

The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the mo.....»»

Thinly traded nano-cap biotech Cytori Therapeutics Inc (NASDAQ: CYTX), which has been trading in penny stock territory for about a year now, could see some activity in the wake of a company announcement Friday.  read more.....»»

AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi i.....»»